Reduction of free radicals in multiple sclerosis: Effect of glatiramer acetate (Copaxone®)

Multiple Sclerosis

Volumn 14, Issue 6, 2008, Pages 739-748

  Iarlori, C ^a   Gambi, D ^a,b   Lugaresi, A ^a   Patruno, A ^a   Felaco, M ^a   Salvatore, M ^c   Speranza, L ^a   Reale, Marcella ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Centre of Excellence on Aging   (Italy)

^c FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS   (Italy)

Author keywords

ELISA; Glatiramer acetate; Inducible nitric oxide synthase; Nitric oxide; Peripheral blood adherent mononuclear cells; Peroxynitrite; Relapsing remitting multiple sclerosis; Superoxide anion; Western blot

Indexed keywords

3 NITROTYROSINE; CYTOKINE; FREE RADICAL; GLATIRAMER; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PEROXYNITRITE; SUPEROXIDE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOMODULATION; IN VITRO STUDY; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; RELAPSE; TH2 CELL;

ADULT; CELLS, CULTURED; FEMALE; FREE RADICALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PEPTIDES; SUPEROXIDES; TYROSINE;

EID: 48349088568     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508088918     Document Type: Article

References (32)

1. Forstermann, U, Kleinert, H. Nitric oxide synthase: expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 1995; 352: 351-364.
2. Moncada, SR, Palmer, MJ, Higgs, EA. Nitric oxide: physiology, pathology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
3. Furlan, R, Rovaris, M, Martinelli Boneschi, F, Khademi, M, Bergami, A, et al. Immunological patterns identifying. disease curse and evolution in multiple sclerosis patients. J Neuroimmunol 2005; 165: 192-200.
4. Bagasra, O, Michaels, FH, Zheng, YM, Bobroski, LE, Spitsin, SV, Fu, ZF, et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A 1995; 92: 12041-12045.
5. Cross, AH, Manning, PT, Stern, MK, Misko, TP. Evidence for the production of peroxynitrite in inflammatory CNS demyelination. J Neuroimmunol 1997; 80: 121-130.
6. Tran, EH, Hardin-Pouzet, H, Varge, G, Owens, T. Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalo-myelitis. J Neuroimmunol 1997; 74: 1211-1229.
7. Smith, KJ, Lassmann, H. The role of nitric oxide in multiple sclerosis. Lancet Neuro 2002; 1: 232-241.
8. Nazliel, B, Taskiran, D, Irkec, C, Kutay, FZ, Pogun, S. Serum nitric oxide metabolites in patients with multiple sclerosis. J Clin Neurosci 2002; 9, 530-532.
9. Giovannoni, G, Miller, DH, Losseff, NA, Sailer, M, Lewellyn-Smith, N, Thompson, AJ, et al. Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. J Neurol 2001; 248: 487-497.
10. Carlson, NG, Rose, JW. Antioxidants in multiple sclerosis: do they have a role in therapy? CNS Drugs 2006; 20: 433-441.
11. De Groot, CJ, Ruuls, SR, Theeuwes, JW, Dijkstra, CD, Van der Valk, P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 1997, 56: 10-20.
12. Hill, KE, Zollinger, LV, Watt, HE, Carlson, NG, Rose, JW. Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: distribution, cellular expression and association with myelin damage. J Neuroimmunol 2004; 151: 171-179.
13. Minagar, A, Alexander, JS. Blood-brain barrier disruption in multiple sclerosis. Multi Scler 2003; 9: 540-549.
14. Comi, G, Filippi, M, Wolinski, JS. European/Canadian multicenter, double-blind, randomised, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity, and burden in patients with relapsing multiple sclerosis: European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-296.
15. Simpson, D, Noble, S, Perry, C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs 2002; 16; 825-850.
16. Teitelbaum, D, Fridkis-Hareli, M, Arnon, R, Sela, M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996; 64: 209-217.
17. Fridkis-Hareli, M, Strominger, JL. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 1998; 160: 4386-4397.
18. Weber, M, Starck, M, Wagenpfell S, Meinl, E, Hohlfeld, R, Farina, C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004; 127: 1370-1378.
19. Prat, A, Biernacki, K, Antel, J. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon β land copolymer-1. J Autoimmunol 2005; 2: 119-124.
20. Aharoni, R, Kayhan, B, Eilam, R, Sela, M, Arnon, R. Glatiramer acetate-specific T cells In the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A 2003, 100: 14157-14162.
21. Pritchard, KA, Groszek, L, Smalley, DM, Sessa, WC, Wu, M, Villalon, P, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Cir Res 1995; 77: 510-518.
22. McDonald, WI, Compston, A, Edan, G, Goodkin, D, Hartung, HP, Lublin, FD, et al. Recommended diagnostic criteria for multiple sclerosis: guielines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
23. Poser, CM, Paty, DW, Scheinberg, I, McDonald, WI, Davis, FA, Ebers, GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
24. Lublin, FD, Reingold, SC. Defining the clinical course of multiple sclerosis: results of an International survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46: 907-911.
25. Kurtzke, JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983, 33: 1444-1452.
26. Al-Omaishi, J, Bashir, R, Gendelman, HE. The cellular immunology of multiple sclerosis. J Leukoc Biol 1999; 65: 444-452.
27. Danilov, AI, Andersson, M, Bavand, N, Wiklund, NP, Olsson, T, Brundin, L. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmun 2003; 136: 112-118.
28. Liu, JS, Zhao, ML, Brosnan, CF, Lee, SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001; 158: 2057-2066.
29. Sarchielli, P, Orlacchio, A, Vicinanza F, Pelliccioli, G, Tognoloni, M, Saccardi, C, et al. Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. J Neuroimmun 1997; 80: 76-86.
30. Lopez-Moratalla, N, Gonzales, A, Aymerich, MS, Lopez-Zabalda, MJ, Pio, R, de Castro, P, et al. Monocyte inducible nitric oxide synthase in Multiple Sclerosis. Regulatory role of nitric oxide. Nitric Oxide: Biol & Chem 1997; 1: 95-104.
31. Duda, PW, Schmied, MC, Cook, SL, Krieger, JI, Hafler, DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 106: 967-976
32. Niedbala, W, Cai, B, Liew, FY. Role of nitric oxide in the regulation of T cells functions. Ann Rheum Dis 2006; 65: 37-40.